Enhanced Killing of Cancer Cells by Poly(ADP-ribose) Polymerase Inhibitors and Topoisomerase I Inhibitors Reflects Poisoning of Both Enzymes

High Cell Surface Death Receptor Expression Determines Type IVersusType II Signaling

(2011) Xue Wei Meng et al.   JOURNAL OF BIOLOGICAL CHEMISTRY

Poly(ADP-ribose) polymerase and XPF–ERCC1 participate in distinct pathways for the repair of topoisomerase I-induced DNA damage in mammalian cells

(2011) Yong-Wei Zhang et al.   NUCLEIC ACIDS RESEARCH

Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells

(2011) A. G. Patel et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Inhibition of helicase activity by a small molecule impairs Werner syndrome helicase (WRN) function in the cellular response to DNA damage or replication stress

(2011) M. Aggarwal et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Immunohistochemical detection of poly(ADP-ribose) polymerase inhibition by ABT-888 in patients with refractory solid tumors and lymphomas

(2010) Sherry X. Yang et al.   CANCER BIOLOGY & THERAPY

DNA Topoisomerases and Their Poisoning by Anticancer and Antibacterial Drugs

(2010) Yves Pommier et al.   CHEMISTRY & BIOLOGY

Evolution of Poly(ADP-ribose) Polymerase-1 (PARP-1) Inhibitors. From Concept to Clinic

(2010) Dana V. Ferraris   JOURNAL OF MEDICINAL CHEMISTRY

The MMS22L-TONSL Complex Mediates Recovery from Replication Stress and Homologous Recombination

(2010) Lara O'Donnell et al.   MOLECULAR CELL

Identification of the MMS22L-TONSL Complex that Promotes Homologous Recombination

(2010) Eris Duro et al.   MOLECULAR CELL

The PARP Side of the Nucleus: Molecular Actions, Physiological Outcomes, and Clinical Targets

(2010) Raga Krishnakumar et al.   MOLECULAR CELL

PARP is activated at stalled forks to mediate Mre11-dependent replication restart and recombination

(2009) Helen E Bryant et al.   EMBO JOURNAL

Phase 0 Clinical Trial of the Poly (ADP-Ribose) Polymerase Inhibitor ABT-888 in Patients With Advanced Malignancies

(2009) Shivaani Kummar et al.   JOURNAL OF CLINICAL ONCOLOGY

PI3K Links NKG2D Signaling to a CrkL Pathway Involved in Natural Killer Cell Adhesion, Polarity, and Granule Secretion

(2009) C. M. Segovis et al.   JOURNAL OF IMMUNOLOGY

Acquired Resistance to Combination Treatment with Temozolomide and ABT-888 Is Mediated by Both Base Excision Repair and Homologous Recombination DNA Repair Pathways

(2009) X. Liu et al.   MOLECULAR CANCER RESEARCH

Discovery of the Poly(ADP-ribose) Polymerase (PARP) Inhibitor 2-[(R)-2-methylpyrrolidin-2-yl]-1H-benzimidazole-4-carboxamide (ABT-888) for the Treatment of Cancer

(2008) Thomas D. Penning et al.   JOURNAL OF MEDICINAL CHEMISTRY

Overcoming S-Phase Checkpoint-Mediated Resistance: Sequence-Dependent Synergy of Gemcitabine and 7-Ethyl-10-hydroxycamptothecin (SN-38) in Human Carcinoma Cell Lines

(2008) M. Galvez-Peralta et al.   MOLECULAR PHARMACOLOGY

Proteome-wide identification of poly(ADP-ribose) binding proteins and poly(ADP-ribose)-associated protein complexes

(2008) Jean-Philippe Gagné et al.   NUCLEIC ACIDS RESEARCH